Cargando…
Chemotherapy in Well Differentiated Neuroendocrine Tumors (NET) G1, G2, and G3: A Narrative Review
Neuroendocrine tumors (NETs) are rare neoplasms with a wide spectrum of clinical behavior, from the long survival of well-differentiated NETs to the dismal prognosis of high-grade neuroendocrine carcinomas (NECs), being G3 NETs a recently recognized intermediate entity. While the role of chemotherap...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9861419/ https://www.ncbi.nlm.nih.gov/pubmed/36675645 http://dx.doi.org/10.3390/jcm12020717 |
_version_ | 1784874836776976384 |
---|---|
author | Zappi, Arianna Persano, Irene Galvani, Linda Parlagreco, Elena Andrini, Elisa Campana, Davide Brizzi, Maria Pia Lamberti, Giuseppe La Salvia, Anna |
author_facet | Zappi, Arianna Persano, Irene Galvani, Linda Parlagreco, Elena Andrini, Elisa Campana, Davide Brizzi, Maria Pia Lamberti, Giuseppe La Salvia, Anna |
author_sort | Zappi, Arianna |
collection | PubMed |
description | Neuroendocrine tumors (NETs) are rare neoplasms with a wide spectrum of clinical behavior, from the long survival of well-differentiated NETs to the dismal prognosis of high-grade neuroendocrine carcinomas (NECs), being G3 NETs a recently recognized intermediate entity. While the role of chemotherapy is well established in NECs, data on NETs mostly derives from small studies, experts’ opinions, and extrapolating results from small-cell lung cancer studies. This narrative review aims to summarize available evidence about the use of chemotherapy in the setting of G1-2 NETs and G3 NETs. We performed literature research in PubMed Library for all articles published up to September 2022 about the efficacy of chemotherapy in NETs. Treatment regimens with STZ-5FU, CAPTEM, and anti-metabolite-based treatment are the most active and tolerated in gastroenteropancreatic NETs (GEP-NETs) G1-G2, while platinum-based regimens (FOLFOX/XELOX) and TEM/CAPTEM showed the best activity in thoracic NETs. Solid evidence about chemotherapy efficacy in G3 NETs is still lacking. Literature data support the use of chemotherapy in low-intermediate grade NETs after the failure of other therapies or if tumor shrinkage is needed. Studies assessing G3 NETs independently from NECs are needed to better understand the role of chemotherapy in this setting. |
format | Online Article Text |
id | pubmed-9861419 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-98614192023-01-22 Chemotherapy in Well Differentiated Neuroendocrine Tumors (NET) G1, G2, and G3: A Narrative Review Zappi, Arianna Persano, Irene Galvani, Linda Parlagreco, Elena Andrini, Elisa Campana, Davide Brizzi, Maria Pia Lamberti, Giuseppe La Salvia, Anna J Clin Med Review Neuroendocrine tumors (NETs) are rare neoplasms with a wide spectrum of clinical behavior, from the long survival of well-differentiated NETs to the dismal prognosis of high-grade neuroendocrine carcinomas (NECs), being G3 NETs a recently recognized intermediate entity. While the role of chemotherapy is well established in NECs, data on NETs mostly derives from small studies, experts’ opinions, and extrapolating results from small-cell lung cancer studies. This narrative review aims to summarize available evidence about the use of chemotherapy in the setting of G1-2 NETs and G3 NETs. We performed literature research in PubMed Library for all articles published up to September 2022 about the efficacy of chemotherapy in NETs. Treatment regimens with STZ-5FU, CAPTEM, and anti-metabolite-based treatment are the most active and tolerated in gastroenteropancreatic NETs (GEP-NETs) G1-G2, while platinum-based regimens (FOLFOX/XELOX) and TEM/CAPTEM showed the best activity in thoracic NETs. Solid evidence about chemotherapy efficacy in G3 NETs is still lacking. Literature data support the use of chemotherapy in low-intermediate grade NETs after the failure of other therapies or if tumor shrinkage is needed. Studies assessing G3 NETs independently from NECs are needed to better understand the role of chemotherapy in this setting. MDPI 2023-01-16 /pmc/articles/PMC9861419/ /pubmed/36675645 http://dx.doi.org/10.3390/jcm12020717 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Zappi, Arianna Persano, Irene Galvani, Linda Parlagreco, Elena Andrini, Elisa Campana, Davide Brizzi, Maria Pia Lamberti, Giuseppe La Salvia, Anna Chemotherapy in Well Differentiated Neuroendocrine Tumors (NET) G1, G2, and G3: A Narrative Review |
title | Chemotherapy in Well Differentiated Neuroendocrine Tumors (NET) G1, G2, and G3: A Narrative Review |
title_full | Chemotherapy in Well Differentiated Neuroendocrine Tumors (NET) G1, G2, and G3: A Narrative Review |
title_fullStr | Chemotherapy in Well Differentiated Neuroendocrine Tumors (NET) G1, G2, and G3: A Narrative Review |
title_full_unstemmed | Chemotherapy in Well Differentiated Neuroendocrine Tumors (NET) G1, G2, and G3: A Narrative Review |
title_short | Chemotherapy in Well Differentiated Neuroendocrine Tumors (NET) G1, G2, and G3: A Narrative Review |
title_sort | chemotherapy in well differentiated neuroendocrine tumors (net) g1, g2, and g3: a narrative review |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9861419/ https://www.ncbi.nlm.nih.gov/pubmed/36675645 http://dx.doi.org/10.3390/jcm12020717 |
work_keys_str_mv | AT zappiarianna chemotherapyinwelldifferentiatedneuroendocrinetumorsnetg1g2andg3anarrativereview AT persanoirene chemotherapyinwelldifferentiatedneuroendocrinetumorsnetg1g2andg3anarrativereview AT galvanilinda chemotherapyinwelldifferentiatedneuroendocrinetumorsnetg1g2andg3anarrativereview AT parlagrecoelena chemotherapyinwelldifferentiatedneuroendocrinetumorsnetg1g2andg3anarrativereview AT andrinielisa chemotherapyinwelldifferentiatedneuroendocrinetumorsnetg1g2andg3anarrativereview AT campanadavide chemotherapyinwelldifferentiatedneuroendocrinetumorsnetg1g2andg3anarrativereview AT brizzimariapia chemotherapyinwelldifferentiatedneuroendocrinetumorsnetg1g2andg3anarrativereview AT lambertigiuseppe chemotherapyinwelldifferentiatedneuroendocrinetumorsnetg1g2andg3anarrativereview AT lasalviaanna chemotherapyinwelldifferentiatedneuroendocrinetumorsnetg1g2andg3anarrativereview |